176 related articles for article (PubMed ID: 20979799)
21. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT).
Morice AH; Celli B; Kesten S; Lystig T; Tashkin D; Decramer M
Respir Med; 2010 Nov; 104(11):1659-67. PubMed ID: 20724131
[TBL] [Abstract][Full Text] [Related]
22. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.
Rennard S; Bantje T; Centanni S; Chanez P; Chuchalin A; D'Urzo A; Kornmann O; Perry S; Jack D; Owen R; Higgins M
Respir Med; 2008 Jul; 102(7):1033-44. PubMed ID: 18479895
[TBL] [Abstract][Full Text] [Related]
23. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD.
Tashkin DP; Donohue JF; Mahler DA; Huang H; Goodwin E; Schaefer K; Hanrahan JP; Andrews WT
Respir Med; 2009 Apr; 103(4):516-24. PubMed ID: 19208459
[TBL] [Abstract][Full Text] [Related]
24. Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids.
Perng DW; Wu CC; Su KC; Lee YC; Perng RP; Tao CW
Respirology; 2006 Sep; 11(5):598-602. PubMed ID: 16916333
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.
Abrahams R; Moroni-Zentgraf P; Ramsdell J; Schmidt H; Joseph E; Karpel J
Respir Med; 2013 Jun; 107(6):854-62. PubMed ID: 23490224
[TBL] [Abstract][Full Text] [Related]
26. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial.
Troosters T; Celli B; Lystig T; Kesten S; Mehra S; Tashkin DP; Decramer M;
Eur Respir J; 2010 Jul; 36(1):65-73. PubMed ID: 20185426
[TBL] [Abstract][Full Text] [Related]
27. A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium.
Vogelmeier C; Aquino TO; O'Brien CD; Perrett J; Gunawardena KA
COPD; 2012 Apr; 9(2):111-20. PubMed ID: 22458939
[TBL] [Abstract][Full Text] [Related]
28. Preoperative use of inhaled tiotropium in lung cancer patients with untreated COPD.
Kobayashi S; Suzuki S; Niikawa H; Sugawara T; Yanai M
Respirology; 2009 Jul; 14(5):675-9. PubMed ID: 19476597
[TBL] [Abstract][Full Text] [Related]
29. Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial.
Tashkin DP
Expert Rev Respir Med; 2010 Jun; 4(3):279-89. PubMed ID: 20524910
[TBL] [Abstract][Full Text] [Related]
30. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group.
Casaburi R; Briggs DD; Donohue JF; Serby CW; Menjoge SS; Witek TJ
Chest; 2000 Nov; 118(5):1294-302. PubMed ID: 11083677
[TBL] [Abstract][Full Text] [Related]
31. Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients.
Ichinose M; Fujimoto T; Fukuchi Y
Respir Med; 2010 Feb; 104(2):228-36. PubMed ID: 19969446
[TBL] [Abstract][Full Text] [Related]
32. The efficacy and safety of tiotropium in Chinese patients with stable chronic obstructive pulmonary disease: a meta-analysis.
Wu Q; Li G; Lei WI; Zhou X
Respirology; 2009 Jul; 14(5):666-74. PubMed ID: 19402836
[TBL] [Abstract][Full Text] [Related]
33. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.
Decramer M; Celli B; Kesten S; Lystig T; Mehra S; Tashkin DP;
Lancet; 2009 Oct; 374(9696):1171-8. PubMed ID: 19716598
[TBL] [Abstract][Full Text] [Related]
34. [Tiotropium (Spiriva) - a long-acting inhaled anticholinergic for the treatment of chronic obstructive pulmonary disease (COPD)].
Beeh KM; Welte T; Buhl R
Pneumologie; 2003 Sep; 57(9):519-25. PubMed ID: 13680472
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of withdrawal of maintenance tiotropium in COPD.
Adams SG; Anzueto A; Briggs DD; Leimer I; Kesten S
Respir Med; 2009 Oct; 103(10):1415-20. PubMed ID: 19523796
[TBL] [Abstract][Full Text] [Related]
36. Additive effects of transdermal tulobuterol to inhaled tiotropium in patients with COPD.
Ichinose M; Seyama K; Nishimura M; Fukuchi Y; Nagai A; Mishima M; Kubo K;
Respir Med; 2010 Feb; 104(2):267-74. PubMed ID: 19875277
[TBL] [Abstract][Full Text] [Related]
37. Effects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary disease.
Casaburi R; Maltais F; Porszasz J; Albers F; Deng Q; Iqbal A; Paden HA; O'Donnell DE;
Ann Am Thorac Soc; 2014 Nov; 11(9):1351-61. PubMed ID: 25289942
[TBL] [Abstract][Full Text] [Related]
38. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.
Tashkin DP; Pearle J; Iezzoni D; Varghese ST
COPD; 2009 Feb; 6(1):17-25. PubMed ID: 19229704
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial.
Tashkin DP; Celli BR; Decramer M; Lystig T; Liu D; Kesten S
COPD; 2012 Jun; 9(3):289-96. PubMed ID: 22432932
[TBL] [Abstract][Full Text] [Related]
40. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.
van Noord JA; Aumann JL; Janssens E; Smeets JJ; Verhaert J; Disse B; Mueller A; Cornelissen PJ
Eur Respir J; 2005 Aug; 26(2):214-22. PubMed ID: 16055868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
